SEC Company Response from Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Jan 3, 2018
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: Jan. 3, 2018 · CIK: 0001607678 · Accession: 0001564590-18-000070
AI Filing Summary & Sentiment
File numbers found in text: 333-222202
Letter
vktx-corresp.htm
Viking Therapeutics, Inc.
12340 El Camino Real, Suite 250
San Diego, CA 92130
January 3, 2018
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
Viking Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 20, 2017
File No. 333-222202
Ladies and Gentlemen:
Reference is hereby made to the letter submitted via EDGAR by Viking Therapeutics, Inc. (the “Registrant”), dated December 29, 2017 (the “Acceleration Request”), which requested that the Registrant’s Registration Statement on Form S-1 (File No. 333-222202) be declared effective at 4:30 p.m., Eastern Time, on January 3, 2018, or as soon thereafter as practicable. The Registrant hereby requests withdrawal of the Acceleration Request.
Thank you for your assistance. Should you have any questions, please contact our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com.
Sincerely,
VIKING THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm vktx-corresp.htm Viking Therapeutics, Inc. 12340 El Camino Real, Suite 250 San Diego, CA 92130 January 3, 2018 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Viking Therapeutics, Inc. Registration Statement on Form S-1 Filed December 20, 2017 File No. 333-222202 Ladies and Gentlemen: Reference is hereby made to the letter submitted via EDGAR by Viking Therapeutics, Inc. (the “Registrant”), dated December 29, 2017 (the “Acceleration Request”), which requested that the Registrant’s Registration Statement on Form S-1 (File No. 333-222202) be declared effective at 4:30 p.m., Eastern Time, on January 3, 2018, or as soon thereafter as practicable. The Registrant hereby requests withdrawal of the Acceleration Request. Thank you for your assistance. Should you have any questions, please contact our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. Sincerely, VIKING THERAPEUTICS, INC. By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer cc:Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)